The Complete Guide to Compounding Pharmacy Requirements (2026)

Quick Answer: Compounding pharmacy requirements include federal and state rules. The FDA sets 503A and 503B classifications. The United States Pharmacopeia (USP) creates standards for sterile, non-sterile, and hazardous drug handling. These rules control how facilities are designed, staff training, and drug quality.

Context: As of 2026, the FDA watches more closely. Recent changes to USP chapters make following these rules more important than ever. This protects patients and helps avoid serious penalties.

Key Takeaway: This guide breaks down all requirement layers. It covers choosing between 503A and 503B. It explains how to follow specific USP standards. You won’t find this clarity in scattered government documents.

Definition Box:

Key Takeaways

• Two-Part System: The Food and Drug Administration (FDA) handles federal oversight. Individual Boards of Pharmacy handle state-level enforcement.
• Business Model Matters: Your operations determine your regulations. Do you compound for individual patients with prescriptions? Or do you make bulk products for healthcare facilities? This choice decides if you’re a 503A pharmacy or 503B outsourcing facility.
• USP Chapters Are Required: The United States Pharmacopeia (USP) General Chapters are mandatory. Chapter 795 covers non-sterile products. Chapter 797 covers sterile products. Chapter 800 covers hazardous drugs. These are the basic quality standards for all compounding.
• Records Are Critical: You must keep detailed records. Document formulations, compounding processes, staff training, and facility cleaning. Good records are as important as equipment. Regulators see poor documentation as a major failure.

Understanding the Core Split: 503A vs. 503B Facilities

The Drug Quality and Security Act (DQSA) created modern compounding rules in the United States. This law made two types of compounding entities. There are 503A pharmacies and 503B outsourcing facilities.

Understanding this difference is the first crucial step. It defines who regulates you. It sets your operational scope. It determines your path to market. A 503A works like a traditional pharmacy focused on individual patient needs. A 503B works more like a specialized manufacturer supplying other healthcare entities.

Key Differences at a Glance

The choice between these two models affects every part of the business. It impacts initial investment and daily operations. Industry data from sources like The FDA Group shows that 503A facilities are more common. But 503B facilities fill a critical need. They provide standardized, large-volume compounded sterile products for hospitals and clinics.

The Comparison Table

Feature	503A Pharmacy	503B Outsourcing Facility
Primary Regulation	State Boards of Pharmacy	Food and Drug Administration (FDA)
Prescription Basis	Must have a patient-specific prescription before compounding	Can compound without a prescription (for “office use” by facilities)
Governing Standards	USP <795>, <797>, <800> & State Pharmacy Laws	USP standards + Current Good Manufacturing Practices (CGMP)
Interstate Shipping	Limited, based on state-specific Memoranda of Understanding (MOUs) or laws	Permitted nationwide
FDA Registration	Not required (licensed by the state)	Voluntary to become a 503B, but required to operate as one; must register annually
Adverse Event Reporting	Varies by state, often less stringent	Mandatory to report all serious adverse events to the FDA
Ideal For	Community pharmacies serving individual patients with unique needs	Large-scale production for hospitals, clinics, and doctor’s offices

Why This Choice Is Your Most Important First Step

Selecting your path is not just a regulatory formality. It is the foundation of your business strategy.

• The 503A Model: This path builds on the traditional pharmacist-patient-prescriber relationship. It works well for community pharmacies that want to offer custom medications. Examples include creating a liquid form of a pill for a child. Or preparing a dye-free medication for an allergic patient. Or combining multiple topical creams. The regulatory burden is significant but managed mainly at the state level. The focus is on small-batch, patient-specific preparations.
• The 503B Model: This path is for entities that want to compound large batches of medications. They sell to hospitals, clinics, and physician offices for administration without first getting a patient-specific prescription. This “office use” capability comes at a price. 503B facilities must voluntarily register with the FDA. They must follow much stricter Current Good Manufacturing Practices (CGMP). This is a manufacturing-oriented model. It requires a much higher investment in facilities, quality control systems, and regulatory compliance personnel.

Understanding USP General Chapters: The Technical Foundation of Compounding

The 503A/503B distinction defines who regulates you. The United States Pharmacopeia (USP) chapters define how you must operate. These chapters are not just guidelines. They are enforceable standards adopted by state boards of pharmacy and the FDA.

They provide the minimum requirements for processes, facilities, and quality control. This ensures patient safety. Achieving compounding pharmacy accreditation often means showing strict adherence to these critical standards.

USP <795>: Requirements for Non-Sterile Preparations

USP Chapter <795> provides standards for compounding non-sterile preparations. These are medications that are not injected or used in the eye. They have a lower risk of microbial contamination.

• What it covers: The most common compounded medications fall under this chapter. This includes creams, ointments, gels, capsules, tablets, and oral liquids.
• Key Requirements:
  • Designated Compounding Area: A specific area must be dedicated to non-sterile compounding. It must be separate from the main dispensing workflow. It needs to be well-lit, clean, and organized.
  • Personnel Training: All staff involved in compounding must be trained. They must demonstrate competency in the required skills. This training must be documented.
  • Beyond-Use Dates (BUDs): The chapter provides a framework for assigning BUDs. These define the timeframe within which the preparation must be used. Recent updates have introduced a more scientific, evidence-based approach to BUD assignment.
  • Documentation: Master Formulation Records (the “recipe”) and Compounding Records (the log for each specific preparation) are mandatory.
  • Quality Control: Procedures must be in place to verify the quality and accuracy of the final preparation.

USP <797>: Requirements for Sterile Preparations

USP Chapter <797> addresses sterile compounding. The risk to the patient is much higher due to the potential for microbial contamination. These preparations bypass the body’s natural defenses.

• What it covers: Injections (e.g., IV bags, syringes), ophthalmic formulations (eye drops), and sterile irrigations.
• Key Requirements:
  • Engineering Controls: This is the most significant requirement. It mandates the use of ISO-classified cleanrooms. This includes a Primary Engineering Control (PEC) like a laminar airflow workbench. It must be located within a Secondary Engineering Control (SEC) or “buffer room.”
  • Environmental Monitoring: Regular air and surface sampling is required. This ensures the cleanroom environment remains in a state of microbial control.
  • Personnel Competency: Staff must undergo rigorous training in aseptic technique. This includes specific, documented procedures for hand hygiene. It covers garbing (donning sterile gowns, gloves, masks, etc.) and sterile manipulation.
  • Sterility Testing: For certain high-risk preparations or large batches, testing must be performed. This confirms the final product is free from contaminants.

Unlike non-sterile compounding, sterile preparations carry a much higher risk of direct patient harm. They demand a state of microbial control similar to pharmaceutical manufacturing.

USP <800>: Handling Hazardous Drugs in Healthcare Settings

USP Chapter <800> is an overlay standard. It focuses on protecting healthcare personnel, patients, and the environment from exposure to hazardous drugs (HDs).

• What it covers: This chapter applies to the handling of all HDs. These are defined by the National Institute for Occupational Safety and Health (NIOSH). This includes many chemotherapy agents, some hormones, and other drugs that are carcinogenic, teratogenic, or have other reproductive toxicities.
• Key Requirements:
  • Containment: HDs must be handled in specific containment areas. This prevents cross-contamination and personnel exposure. This requires negative pressure rooms for sterile and non-sterile HD compounding.
  • Engineering Controls: Specific Containment-PECs (C-PECs) and Containment-SECs (C-SECs) are required. These are externally vented.
  • Personal Protective Equipment (PPE): The chapter specifies the exact type of PPE required. This includes double gloves, impermeable gowns, and respiratory protection in some cases.
  • Safe Practices: It outlines policies for every stage of the drug’s lifecycle. This covers receipt and storage to compounding, administration, and disposal.

It is crucial to understand that USP <800> is not a standalone chapter. Its requirements apply in addition to those of <795> and <797> whenever hazardous drugs are handled.

Which Path Is Right for You? A Decision Framework

Choosing between the 503A and 503B models can be confusing. This simplified decision tree can help clarify the correct path based on your intended business operations.

• START HERE: Do you plan to compound medications based only on valid, patient-specific prescriptions?
  • ➡️ YES: You are on the path to becoming a 503A Pharmacy.
    • Next Question: Will you be preparing sterile products (e.g., injections, eye drops)?
      • ➡️ YES: You must comply with your State Board of Pharmacy regulations, USP <797>, and USP <795>.
      • ➡️ NO: You will only be doing non-sterile compounding. You must comply with State Board regulations and USP <795>.
    • Final Check: Will you handle any hazardous drugs (as defined by the NIOSH list)? If yes, you must also design your facility and train your staff to comply with USP <800>.
  • ➡️ NO: You want to compound in bulk for “office use” or sell to healthcare facilities without first receiving patient-specific prescriptions.
    • ➡️ RESULT: You must operate as a 503B Outsourcing Facility. This requires you to register with the FDA. You must fully comply with Current Good Manufacturing Practices (CGMP). You also need to follow all relevant USP chapters (<795>, <797>, and <800>).

The 7-Step Timeline to a Compliant Compounding Pharmacy

Establishing a fully compliant compounding pharmacy is a complex, multi-stage project. This timeline provides a high-level overview of the critical phases. For a more detailed walkthrough, you can explore resources on how to Open a Pharmacy.

1. Month 1-2: Research & Strategic Planning. This is the foundational stage. Decide definitively between the 503A and 503B models. Develop a comprehensive business plan. Detail your service offerings, target market, and financial projections. Secure adequate funding to cover the significant costs of build-out, equipment, and licensing.
2. Month 3: Legal & Corporate Setup. Form your business entity (e.g., LLC, S-Corp). It is highly advisable to engage legal counsel specializing in pharmacy and healthcare law. This ensures your corporate structure is sound and helps navigate the complex regulatory environment.
3. Month 4-7: Facility Design & Build-Out. This is often the most capital-intensive phase. Hire architects and consultants with proven experience in USP-compliant facilities. The pharmacy design must precisely match the requirements of your chosen path (503A/B) and services (sterile/non-sterile/hazardous). Construction of cleanrooms, installation of HVAC systems for pressure differentials, and selection of appropriate surface materials are critical.
4. Month 8-9: Licensing & Registration. Begin the application process for all necessary licenses. This includes your State Board of Pharmacy license. You need a DEA registration for handling controlled substances. You need FDA registration if you are a 503B facility. This process often has the longest lead time and should be started as soon as you have a physical address.
5. Month 10: SOP Development & Equipment Validation. Write detailed Standard Operating Procedures (SOPs) for every single process. This covers how staff wash their hands to how a final product is labeled. Install, calibrate, and validate all compounding equipment (e.g., hoods, balances, mixers) to ensure it functions as intended.
6. Month 11: Staffing, Training & Competency. Hire qualified pharmacists and technicians. Conduct and carefully document comprehensive training on all SOPs. For sterile compounding, this includes extensive training and testing on garbing procedures and aseptic technique.
7. Month 12: Final Inspections & Go-Live. Schedule and undergo final inspections from the State Board of Pharmacy and/or the FDA. Once you pass, you can procure your initial inventory of Active Pharmaceutical Ingredients (APIs) from reputable, FDA-registered suppliers. With all licenses, procedures, and personnel in place, you can officially begin operations.

Key Requirement Categories: A Detailed Checklist

Compliance is not a single action but a continuous state of adherence across multiple domains. Below is a checklist of the core categories of requirements every compounding pharmacy must address.

• Personnel Requirements:
  • A designated Pharmacist-in-Charge (PIC) who is responsible for all compounding activities and has documented expertise.
  • Initial and ongoing training for all compounding staff. Include written or practical competency assessments.
  • Strict adherence to documented garbing and hygiene standards. This is especially important before entering cleanroom environments.
• Facility & Environmental Requirements:
  • Physically separate and clearly marked areas for non-sterile, sterile, and hazardous drug compounding.
  • For sterile compounding, a validated cleanroom suite with proper air quality (HEPA filtration). Include pressure differentials between rooms and controlled temperature and humidity.
  • Surfaces (floors, walls, ceilings, workstations) that are smooth, impervious, non-porous, and easily cleanable. This prevents microbial contamination.
  • Adequate lighting for performing detailed tasks and plumbing with hands-free sinks located in appropriate areas.
• Drug & Component Requirements:
  • All Active Pharmaceutical Ingredients (APIs) must be sourced from FDA-registered suppliers.
  • A Certificate of Analysis (CofA) must be on file for each lot of ingredients. This verifies its identity, quality, and purity.
  • A formal, documented process for receiving, quarantining, testing (if necessary), storing, and handling all raw materials. This prevents mix-ups or degradation.
• Documentation & Record-Keeping:
  • Master Formulation Records: The detailed “recipe” for each unique preparation you compound.
  • Compounding Records: A specific record for every preparation made. Document lot numbers of ingredients used, quantities, the person who prepared it, and the assigned BUD.
  • A library of all Standard Operating Procedures (SOPs). Include training logs for personnel, equipment calibration and maintenance logs, and daily/monthly cleaning logs for the facility.

Frequently Asked Questions (FAQ)

• Q: What is the difference between compounding and manufacturing?
  • A: The key difference is the patient. Compounding is the act of creating a drug for an identified individual patient based on a valid prescription from a licensed practitioner. Manufacturing, in contrast, is the mass production of drugs without specific prescriptions. These are then sold to the broader market and are subject to the FDA’s full new drug approval process.
• Q: Can a regular retail pharmacy also be a compounding pharmacy?
  • A: Yes, many retail pharmacies perform what is known as simple or Level A non-sterile compounding (e.g., mixing a cream). However, engaging in more complex non-sterile or any sterile compounding requires a significant investment. You must meet the much stricter facility, training, and documentation requirements outlined in USP <795> and <797>.
• Q: How often are compounding pharmacies inspected?
  • A: This varies by regulatory body. 503A pharmacies are primarily inspected by their State Board of Pharmacy. The typical inspection cycle is every 1 to 3 years. This can be more frequent if issues are found. 503B outsourcing facilities are inspected by the FDA on a risk-based schedule. This is often more frequent and more intensive than state-level inspections.
• Q: What are the most common reasons for a failed inspection?
  • A: According to published FDA 483 observations and state board disciplinary actions, the most common failures include improper garbing and hygiene by personnel. Others are inadequate or undocumented environmental monitoring of cleanrooms, incomplete or missing documentation (especially Compounding Records), and incorrect assignment of Beyond-Use Dates (BUDs) that are not supported by stability data.

---

🚀 Authority Amplifiers

• About the Author: Steven Guo is an industry expert in commercial facility planning and operational outfitting. With over a decade of experience, he specializes in the intersection of regulatory requirements and physical infrastructure. He focuses on material selection, workflow optimization, and efficient space utilization for specialized commercial environments like pharmacies. His work helps businesses translate complex compliance standards into functional, real-world designs.
• Trust Signals:
  • Data Methodology: The information in this guide was compiled by reviewing the official text of USP General Chapters <795>, <797>, and <800>. It includes FDA guidance documents for industry (including the Drug Quality and Security Act). It also includes a comparative analysis of pharmacy laws from California, Texas, Florida, and New York to provide a representative sample of state-level requirements.
  • Limitations Disclosure: This article is for informational purposes only and does not constitute legal or regulatory advice. Always consult with a qualified attorney and a pharmacy compliance consultant before making business decisions. Regulations are subject to change and interpretation. This content is accurate as of Q1 2026.